CoChat

Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis

Open access
Groza, Diana, Gehrig, Sebastian, Kudela, Pavol, Holcmann, Martin, Pirker, Christine, Dinhof, Carina, Schueffl, Hemma H., Sramko, Marek, Hoebart, Julia, Alioglu, Fatih, Grusch, Michael, Ogris, Manfred, Lubitz, Werner, Keppler, Bernhard K., Pashkunova-Martic, Irena, Kowol, Christian R., Sibilia, Maria, Berger, Walter, Heffeter, Petra · 2018 · OncoImmunology
Cited by 61

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality worldwide. At late stage of the disease CRC often shows (multiple) metastatic lesions in the peritoneal cavity which cannot be efficiently targeted by systemic chemotherapy. This is one major factor contributing to poor prognosis. Oxaliplatin is one of the most commonly used systemic treatment options for advanced CRC. However, drug resistance - often due to insufficient drug delivery - is still hampering successful treatment. The anticancer activity of oxaliplatin includes besides DNA damage also a strong immunogenic component. Consequently, the aim of this study was to investigate the effect of bacterial ghosts (BGs) as adjuvant immunostimulant on oxaliplatin efficacy. BGs are empty envelopes of gram-negative bacteria with a distinct immune-stimulatory potential. Indeed, we were able to show that the combination of BGs with oxaliplatin treatment had strong synergistic anticancer activity against the CT26 allograft, resulting in prolonged survival and even a complete remission in this murine model of CRC carcinomatosis. This synergistic effect was based on an enhanced induction of immunogenic cell death and activation of an efficient T-cell response leading to long-term anti-tumor memory effects. Taken together, co-application of BGs strengthens the immunogenic component of the oxaliplatin anticancer response and thus represents a promising natural immune-adjuvant to chemotherapy in advanced CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2018.1424676

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 61

Metadata

Authors
Groza, D., Gehrig, S., Kudela, P., Holcmann, M., Pirker, C., Dinhof, C., Schueffl, H. H., Sramko, M., Hoebart, J., Alioglu, F., Grusch, M., Ogris, M., Lubitz, W., Keppler, B. K., Pashkunova-Martic, I., Kowol, C. R., Sibilia, M., Berger, W., & Heffeter, P.
Venue
OncoImmunology
Published
2018-02-16
Volume
7
Issue
5
Pages
e1424676-e1424676
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2783688279
Cited by
61
References
6
FWCI
1.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. https://app.cochat.ai/papers/10.1080/2162402x.2018.1424676
The paper
Groza, D., Gehrig, S., Kudela, P., Holcmann, M., Pirker, C., Dinhof, C., Schueffl, H. H., Sramko, M., Hoebart, J., Alioglu, F., Grusch, M., Ogris, M., Lubitz, W., Keppler, B. K., Pashkunova-Martic, I., Kowol, C. R., Sibilia, M., Berger, W., & Heffeter, P. (2018). Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. OncoImmunology. https://doi.org/10.1080/2162402x.2018.1424676

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.